Kintara Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 17
- Market Cap
- -
- Website
- http://www.kintara.com
- Introduction
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)
- Conditions
- Cutaneous Breast Cancer
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Kintara Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05374915
- Locations
- 🇺🇸
Montefiore Einstein Center for Cancer Care, Bronx, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Expanded Access to VAL-083
- Conditions
- Cancer
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Kintara Therapeutics, Inc.
- Registration Number
- NCT03138629
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
- Conditions
- GliomaGlioblastoma MultiformeGBMBrain CancerGlioblastoma
- Interventions
- Drug: VAL-083 (Dianhydrogalactitol)
- First Posted Date
- 2017-02-13
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Kintara Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03050736
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, China
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
- Conditions
- GBMBrain CancerGliomaGlioblastoma MultiformeGlioblastoma
- Interventions
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Kintara Therapeutics, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT02717962
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
News
TuHURA Biosciences and Kintara Therapeutics Complete Merger, Focus on Novel Immunotherapies
TuHURA Biosciences and Kintara Therapeutics have finalized their merger, creating a combined entity named TuHURA Biosciences, Inc., focused on advancing cancer immunotherapies.
Kintara Therapeutics Announces Corporate Updates and REM-001 Clinical Study Progress
Kintara Therapeutics is set to hold a special meeting on September 20, 2024, to approve its merger with TuHURA Biosciences, aiming to enhance its oncology pipeline.